Wyniki wyszukiwania - BazTech

1

Wykorzystanie bakterii w leczeniu nowotworów - dotychczasowe osiągnięcia i potencjalne zastosowania kliniczne

Dróżdż Mateusz, Dudek Barbara

Laboratorium - Przegląd Ogólnopolski

|

2021

|

nr 2

40--45

PL

Konwencjonalne terapie, tj. chemioterapia i radioterapia, stanowią "złoty standard" w leczeniu chorób nowotworowych. Jednakże, potencjalne skutki uboczne oraz możliwa toksyczność tych metod ugruntowują potrzebę odkrycia alternatywnych strategii. Wykorzystanie bakterii w leczeniu nowotworów stanowi nową opcję terapeutyczną ze względu na ich unikalne właściwości (tj. obecność toksyn i enzymów zewnątrzkomórkowych, ruchliwość, beztlenowy tryb życia, immunostymulacja, łatwość modyfikacji genetycznych i ich eliminacji przez antybiotyki). W niniejszym artykule podsumowano najnowsze doniesienia naukowe dotyczące roli bakterii, tj. Salmonella sp., Clostridium sp., Listeria monocytogenes, Escherichia coli i Corynebacterium diphterioe w regresji guza.

EN

Conventional therapies, such as chemotherapy and radiotherapy, are still the "gold standard" in the cancer treatment. However, their potential side effects and toxicity reinforce the need to discover alternative strategies. The use of bacteria in the cancer treatment is a new therapeutic approach due to their unique properties (i.e. presence of toxins and extra cellular enzymes, mobility, anaerobic lifestyle, immunostimulation, case of genetic modification and their elimination by antibiotics). This article summarizes the latest scientific reports on the role of bacteria such as Salmonella sp., Clostridium sp, Listeria monocytogenes, Escherichia coli and Corynebacterium diphteriae in tumor regression.

2

Cure for Type 1 diabetes with biotechnology – how far we are from clinical application?

Wszoła Michał

Engineering of Biomaterials

|

2021

|

Vol. 24, no. 163

10

3

Clinical advantages of using unflattened 6-MV and 10-MV photon beams generated by the medical accelerator Elekta Versa HD based on their dosimetric parameters in comparison to conventional beams

Baic Błażej, Kozłowska Beata, Kwiatkowski Robert, Dybek Marcin

Nukleonika

|

2019

|

Vol. 64, No. 3

77--86

EN

Photon beams with wide energy ranges from 4 MV to 25 MV are commonly used in radiotherapy nowadays. In recent years, there has been a strong interest in a certain modification of a radiotherapeutic apparatus by the application of the so-called flattening filter-free (FFF) beam. Several advantages of FFF beams over standard flattening filter (FF) beams are noticed, and this technical solution has aroused great interest among radiotherapeutic facilities. The goal of the present study is to investigate the differences between the conventional FF and unflattened FFF 6-MV and 10-MV photon beams in some basic dosimetric parameters and their influence on the whole radiotherapeutic treatment. The data provided here include the detailed characteristics as follows: percent depth dose (PDD), beam profile, edge of a half-profile, total scatter correction factor (TSCF) and head scatter correction factor (HSCF) for FF and FFF 6-MV and 10-MV photon beams from the Elekta Versa HD accelerator in the Katowice Oncology Center in Poland.

4

Pochodne akrydyny/akrydonu - synteza, aktywność biologiczna i zastosowanie kliniczne

Dzierzbicka K., Kawzowicz A., Koc A., Kukowska-Kaszuba M.

Wiadomości Chemiczne

|

2009

|

[Z] 63, 1-2

107-139

EN

Nowadays the battle with tumor diseases and bacterial infections is an important test for the scientists. Therefore a lot of attention is focused on obtaining novel, more effective, selectively acting and less toxic drugs. Because of that reason, compounds with wide range of action like acridines/acridones are of great interest for scientists. This study contains synthesis and biological activity of acridine/acridone derivatives which are used in medicine as an antitumor agents and those which are at clinical trials. Among the synthetic methods there are modifications of Ullmann synthesis [2, 3, 9]. Lately Belmont et al. [11, 12] described a new methodology for the synthesis of 1,3,7-trisubstituted acridines, 1-amino-acridine and tetrahydro-cyclopenta[c]acridine-2,5-diones (Scheme 5). The starting materials are commercially available quinolines. Among acridine/acridone group there are compounds with diffe-rent molecular targets, e.g. topoisomerase inhibitors [1, 19-33], telomerase inhibitors [1, 34], protein-kinases inhibitors [36-40], P-glycoproteine inhibitors [56, 57, 76], conjugates with metals [1] and hypoxia-selective derivatives [2, 41-55]. This paper also describes compounds useful in Alzheimer disease [5, 16], antibacterial [2, 5], antiparasites [4, 5] and antiviral infections [5, 13, 14].